Description

MESACOL OD TAB (1X15)

Indications

Mesacol OD Tab (Mesalazine) is primarily indicated for the treatment of ulcerative colitis and Crohn’s disease, particularly in patients experiencing mild to moderate symptoms. It is also used to maintain remission in patients who have previously experienced flare-ups of these inflammatory bowel diseases. Mesalazine works by targeting the inflamed areas of the gastrointestinal tract, thereby reducing inflammation and promoting healing.

Mechanism of Action

Mesalazine, the active ingredient in Mesacol OD Tab, is a 5-aminosalicylic acid (5-ASA) compound. Its mechanism of action involves the inhibition of leukotriene synthesis and the scavenging of free radicals, which contribute to the inflammatory process in the gut. Mesalazine exerts its therapeutic effects topically on the colonic mucosa, thereby reducing inflammation and preventing the recurrence of ulcerative colitis and Crohn’s disease. By modulating the immune response and inhibiting the production of pro-inflammatory cytokines, Mesalazine helps to restore the integrity of the intestinal lining.

Pharmacological Properties

Mesalazine is well-absorbed in the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 4 hours after oral administration. It is primarily metabolized in the liver, with a small percentage excreted unchanged in the urine. The drug has a half-life of approximately 6 to 10 hours, allowing for once-daily dosing in the extended-release formulation. Mesalazine is known for its localized action, which minimizes systemic side effects compared to other anti-inflammatory agents.

Contraindications

Mesacol OD Tab is contraindicated in patients with known hypersensitivity to mesalazine or any of its components. It should not be used in individuals with severe renal impairment, as the drug can exacerbate kidney function. Additionally, caution is advised in patients with a history of gastrointestinal obstruction or severe liver disease. Pregnant and breastfeeding women should consult their healthcare provider before using this medication.

Side Effects

Common side effects of Mesacol OD Tab may include gastrointestinal disturbances such as abdominal pain, diarrhea, nausea, and vomiting. Other potential side effects include headache, dizziness, and fatigue. Rare but serious side effects may involve renal impairment, pancreatitis, and hypersensitivity reactions such as rash, fever, and eosinophilia. Patients should be monitored for any unusual symptoms, particularly during the initial stages of treatment.

Dosage and Administration

The recommended dosage of Mesacol OD Tab for adults is typically 800 mg to 1600 mg per day, administered as a single dose or divided into two doses. For children aged 6 years and older, the dosage is usually based on body weight and should be determined by a healthcare provider. It is important to take Mesacol OD Tab with sufficient fluids to enhance absorption and minimize gastrointestinal discomfort. Patients should adhere to the prescribed regimen and consult their healthcare provider if they miss a dose.

Interactions

Mesacol OD Tab may interact with other medications, particularly those that affect renal function. Non-steroidal anti-inflammatory drugs (NSAIDs) and other nephrotoxic agents should be used with caution in patients receiving Mesalazine, as they may increase the risk of renal impairment. Additionally, the use of anticoagulants and antiplatelet agents may require careful monitoring due to the potential for increased bleeding risk. It is essential for patients to inform their healthcare provider of all medications they are taking to avoid possible interactions.

Precautions

Before starting treatment with Mesacol OD Tab, patients should undergo a thorough medical evaluation to assess for any pre-existing conditions that may contraindicate its use. Regular monitoring of renal function is recommended, especially in patients with a history of kidney disease. Patients should also be advised to maintain adequate hydration during treatment. Those with a history of hypersensitivity to sulfasalazine or other 5-ASA compounds should use Mesacol with caution. It is crucial to follow the healthcare provider’s instructions regarding dosage and duration of therapy to minimize the risk of adverse effects.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of Mesacol in managing ulcerative colitis and Crohn’s disease. A randomized controlled trial published in the Journal of Crohn’s and Colitis showed that Mesalazine significantly reduced the severity of symptoms and induced remission in patients with active ulcerative colitis compared to placebo. Another study indicated that Mesalazine was effective in maintaining remission in patients with quiescent ulcerative colitis, with a favorable safety profile. These studies underscore the importance of Mesacol OD Tab as a cornerstone in the management of inflammatory bowel diseases.

Conclusion

Mesacol OD Tab (Mesalazine) is a valuable therapeutic option for patients suffering from ulcerative colitis and Crohn’s disease. Its targeted action on the gastrointestinal mucosa, combined with a favorable safety profile, makes it an essential component of inflammatory bowel disease management. Patients should be well-informed about the potential side effects and interactions associated with Mesacol, and regular follow-up with healthcare providers is essential to ensure optimal treatment outcomes.